Bristol-Myers Squibb Co. (BMY) News
Filter BMY News Items
BMY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BMY News Highlights
- BMY's 30 day story count now stands at 81.
- Over the past 21 days, the trend for BMY's stories per day has been choppy and unclear. It has oscillated between 1 and 17.
- HCM, DRUG and MET are the most mentioned tickers in articles about BMY.
Latest BMY News From Around the Web
Below are the latest news stories about Bristol Myers Squibb Co that investors may wish to consider to help them evaluate BMY as an investment opportunity.
Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising DealsBiohaven inked a pair of deals Friday to outfit its pipeline with several new drugs, but BHVN stock plummeted on quarterly losses. |
Iovance (IOVA) Announces Wider-Than-Anticipated Q4 LossIovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022. |
Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences DealsView more earnings on BHVNSee more from BenzingaBlood Clot Risk After First AstraZeneca COVID-19 Shot Very Small - UK Study ShowsModerna Adds Three New mRNA-Based Development Programs To Its Pipeline© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. |
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1...PRINCETON, N.J., February 25, 2022--BMS Receives Positive CHMP Opinion for Opdivo plus Chemotherapy for First-Line Treatment of Patients with Unresectable, Advanced, Recurrent.... |
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma...PRINCETON, N.J., February 25, 2022--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo plus Yervoy for First-line Treatment of Patients with.... |
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers SquibbBiohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that it entered into a worldwide license agreement with Bristol Myers Squibb (NYSE: BMY) for the development and commercialization rights to taldefgrobep alfa, a novel, Phase 3-ready anti-myostatin adnectin. Taldefgrobep is the third development asset licensed to Biohaven from Bristol Myers Squibb and a clinical trial for Spinal Muscular Atrophy (SMA) is expected to begin in 2022. |
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%PRINCETON, N.J., February 25, 2022--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo as Adjuvant Treatment for Patients with Radically Resected.... |
Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues LagClovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. |
10 Best Dividend Stocks to Buy According to Kahn BrothersIn this article, we discuss the 10 best dividend stocks to buy according to Kahn Brothers. You can skip our detailed analysis of the hedge fund’s investment philosophy, and go directly to read 5 Best Dividend Stocks to Buy According to Kahn Brothers. Kahn Brothers Group, an investment management firm, was founded by Irving Kahn, […] |
Kim Schrier Stock Portfolio: 10 Stocks To ConsiderIn this article, we discuss the 10 stocks to consider in the portfolio of Kim Schrier. If you want to skip our detailed analysis of these stocks, go directly to Kim Schrier Stock Portfolio: 5 Stocks To Consider. Kim Schrier is a physician and politician born in California. She is presently a member of the […] |